William Blair remains bullish on Rocket following FDA discussion commentary

William Blair analyst Raju Prasad notes that on Thursday, Rocket Pharmaceuticals announced updates from the company’s end-of-Phase 1 meeting with the FDA regarding RP-A501, its Danon disease program. Discussions with the FDA were largely in agreement and seemingly aligned with the agency’s expectations, the analyst states. Prasad believes the FDA discussion commentary signals positive outlook on upcoming design submission of pivotal trial in Danon disease. He has an Outperform rating on the shares.